- Trials with a EudraCT protocol (2,660)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2,660 result(s) found for: Best disease.
Displaying page 1 of 133.
EudraCT Number: 2016-002584-33 | Sponsor Protocol Number: CINC424C2301 | Start Date*: 2017-01-23 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||||||||||||
Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran... | ||||||||||||||||||||||||||||
Medical condition: corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) AT (Completed) FR (Completed) NO (Completed) SE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PT (Completed) HU (Completed) BG (Completed) PL (Completed) NL (Completed) GR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003412-37 | Sponsor Protocol Number: 323/12 | Start Date*: 2015-08-10 | |||||||||||
Sponsor Name:Keele University | |||||||||||||
Full Title: Improving outcomes for patients with hip osteoarthritis: a randomised controlled trial | |||||||||||||
Medical condition: Hip osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003653-16 | Sponsor Protocol Number: S62092 | Start Date*: 2019-03-21 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study | |||||||||||||
Medical condition: Birdshot Uveitis HLA A29 retinochoroiditis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001492-37 | Sponsor Protocol Number: Z-AMD | Start Date*: 2019-11-01 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study | |||||||||||||
Medical condition: Neovascular Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003162-41 | Sponsor Protocol Number: ET2012000058 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: A randomized, multicenter, open-label, phase II study of the optimal scheme of administration of pazopanib in thyroid carcinoma | |||||||||||||
Medical condition: Iodine refractory Differentiated Thyroid Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002887-26 | Sponsor Protocol Number: CRAD001T2302 | Start Date*: 2012-04-26 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ... | |||||||||||||
Medical condition: Advanced neuroendocrine tumor (NET) of GI or lung origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed) NO (Completed) NL (Completed) GR (Completed) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004332-30 | Sponsor Protocol Number: ET18-291 | Start Date*: 2020-04-24 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imati... | ||
Medical condition: Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004359-35 | Sponsor Protocol Number: ICEA2020.1 | Start Date*: 2020-10-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Induction of Cure in Early Arthritis | |||||||||||||
Medical condition: early unclassified arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004432-38 | Sponsor Protocol Number: CINC424D2301 | Start Date*: 2017-10-11 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharma AG | ||||||||||||||||||||||||||||
Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel... | ||||||||||||||||||||||||||||
Medical condition: corticosteroid refractory chronic Graft vs Host Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Completed) FR (Completed) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004409-30 | Sponsor Protocol Number: PS-CLL-009 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL) | |||||||||||||
Medical condition: Previously Untreated Chronic Lymphophatic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002569-20 | Sponsor Protocol Number: BIELEFELD-Janssen-PHRCN-2017 | Start Date*: 2018-11-06 | |||||||||||
Sponsor Name:CHU Dijon Bourgogne | |||||||||||||
Full Title: A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of ustekinumab in association with prednisone, for the treatment of non-infectious severe uveitis (NISU) | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001544-31 | Sponsor Protocol Number: PATP1001 | Start Date*: 2007-04-12 |
Sponsor Name:Moorfields Eye Hospital | ||
Full Title: A randomised, double-masked, phase 3 study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovasculariza... | ||
Medical condition: Exudative age-related macular degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-006141-19 | Sponsor Protocol Number: UMCG-RR#202000930 | Start Date*: 2021-05-21 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Fluorescence guided surgery for intra-operative detection of meningioma using Bevacizumab-IRDye800CW | |||||||||||||
Medical condition: meningioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003865-11 | Sponsor Protocol Number: NEOD001-CL002 | Start Date*: 2015-11-27 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chai... | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended) GR (Completed) PL (Prematurely Ended) DK (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005154-44 | Sponsor Protocol Number: OPERA | Start Date*: 2006-03-02 | |||||||||||
Sponsor Name:Universitätsklinikum Hamburg-Eppendorf | |||||||||||||
Full Title: OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC Open, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatme... | |||||||||||||
Medical condition: metastasized colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002976-32 | Sponsor Protocol Number: unknown | Start Date*: 2007-09-06 |
Sponsor Name:TIPharma | ||
Full Title: COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis. | ||
Medical condition: Patients with early rheumatoid arthritis wil be treated with a combination therapy: COBRA according to BEST or a modified COBRA schedule (COBRA-light). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001363-22 | Sponsor Protocol Number: TH-CR-302 | Start Date*: 2004-12-10 | |||||||||||
Sponsor Name:Threshold Pharmaceuticals | |||||||||||||
Full Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine | |||||||||||||
Medical condition: Previously treated metastatic pancreatic adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006233-40 | Sponsor Protocol Number: CRFB002ADE04 | Start Date*: 2007-08-06 | |||||||||||
Sponsor Name:Department of Ophthalmology, Bonn University | |||||||||||||
Full Title: Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every ... | |||||||||||||
Medical condition: Typical findings in Type 2 idiopathic macular telangiectasia (type2-IMT)are parafoveal ectatic capillaries, The disease is characterized by a slow decrease in visual acuity, reading difficulties an... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003577-34 | Sponsor Protocol Number: 2022/702 | Start Date*: 2023-01-30 |
Sponsor Name:CHU de Besancon | ||
Full Title: Induction regorafenib in combination with metronomic cyclophosphamide, capecitabine and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer. An open-label randomiz... | ||
Medical condition: cancer colorectal métastatique | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004318-14 | Sponsor Protocol Number: NEOD001-201 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Prothena Therapeutics Limited | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction | |||||||||||||
Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
